4.7 Review

Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment

期刊

NUTRIENTS
卷 13, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/nu13113732

关键词

anemia of chronic disease; anemia of inflammation; iron; hepcidin; erythropoietin; infection; cancer; chronic kidney disease; chronic heart failure; auto-immune disease; macrophage

向作者/读者索取更多资源

Anemia is common in patients with inflammatory disorders and is mainly caused by disturbances in iron metabolism. Treatment should focus on addressing the underlying inflammatory disease to normalize hemoglobin levels and prevent the risks associated with anemia. New therapies targeting hepcidin modifications and hypoxia inducible factors show promise but require further evaluation in clinical trials for effectiveness in treating anemia of inflammation in ill patients.
Anemia is very common in patients with inflammatory disorders. Its prevalence is associated with severity of the underlying disease, and it negatively affects quality of life and cardio-vascular performance of patients. Anemia of inflammation (AI) is caused by disturbances of iron metabolism resulting in iron retention within macrophages, a reduced erythrocyte half-life, and cytokine mediated inhibition of erythropoietin function and erythroid progenitor cell differentiation. AI is mostly mild to moderate, normochromic and normocytic, and characterized by low circulating iron, but normal and increased levels of the storage protein ferritin and the iron hormone hepcidin. The primary therapeutic approach for AI is treatment of the underlying inflammatory disease which mostly results in normalization of hemoglobin levels over time unless other pathologies such as vitamin deficiencies, true iron deficiency on the basis of bleeding episodes, or renal insufficiency are present. If the underlying disease and/or anemia are not resolved, iron supplementation therapy and/or treatment with erythropoietin stimulating agents may be considered whereas blood transfusions are an emergency treatment for life-threatening anemia. New treatments with hepcidin-modifying strategies and stabilizers of hypoxia inducible factors emerge but their therapeutic efficacy for treatment of AI in ill patients needs to be evaluated in clinical trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据